Cargando…
Use of the CHA(2)DS(2)VASc score to reduce utilisation of transoesophageal echocardiography prior to ablation for atrial fibrillation
Transoesophageal echocardiography (TOE) is frequently performed prior to atrial fibrillation (AF) ablation to exclude left atrial appendage (LAA) thrombus. However, patients undergoing AF ablation are usually anticoagulated, thus making the presence of thrombus unlikely in most cases. This study aim...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633057/ https://www.ncbi.nlm.nih.gov/pubmed/28864464 http://dx.doi.org/10.1530/ERP-17-0042 |
_version_ | 1783269820892971008 |
---|---|
author | Atkinson, Charlotte Hinton, Jonathan Gaisie, Edmund B Yue, Arthur M Roberts, Paul R Rakhit, Dhrubo J Shah, Benoy N |
author_facet | Atkinson, Charlotte Hinton, Jonathan Gaisie, Edmund B Yue, Arthur M Roberts, Paul R Rakhit, Dhrubo J Shah, Benoy N |
author_sort | Atkinson, Charlotte |
collection | PubMed |
description | Transoesophageal echocardiography (TOE) is frequently performed prior to atrial fibrillation (AF) ablation to exclude left atrial appendage (LAA) thrombus. However, patients undergoing AF ablation are usually anticoagulated, thus making the presence of thrombus unlikely in most cases. This study aimed to determine whether the CHA(2)DS(2)VASc scoring system can be used to identify patients that do not require TOE prior to AF ablation. In this single-centre retrospective study, local institutional and primary care databases and electronic patient records were searched to identify patients that had undergone TOE prior to AF ablation. Patient demographics, CHA(2)DS(2)VASc score, TOE findings and anticoagulation status were collected for analysis. Over a 7-year period (2008–2014), 332 patients (age 57 ± 10 years; 74% male) underwent TOE prior to proposed AF ablation. CHA(2)DS(2)VASc scores of 0, 1, 2 and >2 were found in 39, 34, 15 and 12% of patients, respectively. The prevalence of LAA thrombus was 0.6% (2 patients) and these 2 patients had risk scores of 2 and 4. No patients with a score of 0 or 1 had LAA thrombus. Patients that are classed as low risk by the CHA(2)DS(2)VASc score do not require a pre-ablation TOE to screen for LAA thrombus provided they are adequately anticoagulated. This would lead to a significant reduction in health care expenditures by reducing unnecessary TOE requests and thereby improve patient experience. |
format | Online Article Text |
id | pubmed-5633057 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-56330572017-10-12 Use of the CHA(2)DS(2)VASc score to reduce utilisation of transoesophageal echocardiography prior to ablation for atrial fibrillation Atkinson, Charlotte Hinton, Jonathan Gaisie, Edmund B Yue, Arthur M Roberts, Paul R Rakhit, Dhrubo J Shah, Benoy N Echo Res Pract Research Transoesophageal echocardiography (TOE) is frequently performed prior to atrial fibrillation (AF) ablation to exclude left atrial appendage (LAA) thrombus. However, patients undergoing AF ablation are usually anticoagulated, thus making the presence of thrombus unlikely in most cases. This study aimed to determine whether the CHA(2)DS(2)VASc scoring system can be used to identify patients that do not require TOE prior to AF ablation. In this single-centre retrospective study, local institutional and primary care databases and electronic patient records were searched to identify patients that had undergone TOE prior to AF ablation. Patient demographics, CHA(2)DS(2)VASc score, TOE findings and anticoagulation status were collected for analysis. Over a 7-year period (2008–2014), 332 patients (age 57 ± 10 years; 74% male) underwent TOE prior to proposed AF ablation. CHA(2)DS(2)VASc scores of 0, 1, 2 and >2 were found in 39, 34, 15 and 12% of patients, respectively. The prevalence of LAA thrombus was 0.6% (2 patients) and these 2 patients had risk scores of 2 and 4. No patients with a score of 0 or 1 had LAA thrombus. Patients that are classed as low risk by the CHA(2)DS(2)VASc score do not require a pre-ablation TOE to screen for LAA thrombus provided they are adequately anticoagulated. This would lead to a significant reduction in health care expenditures by reducing unnecessary TOE requests and thereby improve patient experience. Bioscientifica Ltd 2017-08-21 /pmc/articles/PMC5633057/ /pubmed/28864464 http://dx.doi.org/10.1530/ERP-17-0042 Text en © 2017 The authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Research Atkinson, Charlotte Hinton, Jonathan Gaisie, Edmund B Yue, Arthur M Roberts, Paul R Rakhit, Dhrubo J Shah, Benoy N Use of the CHA(2)DS(2)VASc score to reduce utilisation of transoesophageal echocardiography prior to ablation for atrial fibrillation |
title | Use of the CHA(2)DS(2)VASc score to reduce utilisation of transoesophageal echocardiography prior to ablation for atrial fibrillation |
title_full | Use of the CHA(2)DS(2)VASc score to reduce utilisation of transoesophageal echocardiography prior to ablation for atrial fibrillation |
title_fullStr | Use of the CHA(2)DS(2)VASc score to reduce utilisation of transoesophageal echocardiography prior to ablation for atrial fibrillation |
title_full_unstemmed | Use of the CHA(2)DS(2)VASc score to reduce utilisation of transoesophageal echocardiography prior to ablation for atrial fibrillation |
title_short | Use of the CHA(2)DS(2)VASc score to reduce utilisation of transoesophageal echocardiography prior to ablation for atrial fibrillation |
title_sort | use of the cha(2)ds(2)vasc score to reduce utilisation of transoesophageal echocardiography prior to ablation for atrial fibrillation |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633057/ https://www.ncbi.nlm.nih.gov/pubmed/28864464 http://dx.doi.org/10.1530/ERP-17-0042 |
work_keys_str_mv | AT atkinsoncharlotte useofthecha2ds2vascscoretoreduceutilisationoftransoesophagealechocardiographypriortoablationforatrialfibrillation AT hintonjonathan useofthecha2ds2vascscoretoreduceutilisationoftransoesophagealechocardiographypriortoablationforatrialfibrillation AT gaisieedmundb useofthecha2ds2vascscoretoreduceutilisationoftransoesophagealechocardiographypriortoablationforatrialfibrillation AT yuearthurm useofthecha2ds2vascscoretoreduceutilisationoftransoesophagealechocardiographypriortoablationforatrialfibrillation AT robertspaulr useofthecha2ds2vascscoretoreduceutilisationoftransoesophagealechocardiographypriortoablationforatrialfibrillation AT rakhitdhruboj useofthecha2ds2vascscoretoreduceutilisationoftransoesophagealechocardiographypriortoablationforatrialfibrillation AT shahbenoyn useofthecha2ds2vascscoretoreduceutilisationoftransoesophagealechocardiographypriortoablationforatrialfibrillation |